Public or large-cap private companies and institutions:
Evaluation is made by a Screening Committee that determines whether the proposed topic contributes to the advancement and/or adoption of personalized medicine.
Applicants notified within ~one week
Focus area: Polymerase Chain Reaction (PCR) systems
Acquired by Bio-Rad for $162M 3 years after starting
DVS Sciences manufactures and globally distributes novel bioanalytical solutions for use in biomarker discovery, biological research and potential future use in clinical applications. The patented multi-parameter technology comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF, and a suite of MAXPAR reagents.
Epizyme discovers and develops small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics.
Genia Technology core technology is the biological nanopore, which reduces the price of sequencing and increases speed, accuracy, and sensitivity by moving away from enzyme-based sequencing methods and optical detection.
Integrated Diagnostics is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage.
NextBio has a mission is to integrate the world's genomic data, enabling researchers and clinicians to develop unprecedented biomedical insights and improve human health. NextBio has built a powerful platform to aggregate, correlate and interpret world's collections of private and public genomic data.
Recombinant Data offers life sciences software solutions for translational research. Their standard software packages are toolkits and frameworks for establishing translational research data warehouses and the analytics utilities to maximize use of those data assets.
Telome Health technology will analyze tissue samples to provide customers with accurate and reliable analyses of telomere biology. This data will be generated by research scientists for the research market, and by qualified personnel in a CLIA certified laboratory for the regulated consumer and pharmaceutical markets.
Vision Gate aims to dramatically improve patient health with the world's first, non-invasive, diagnostic test for early lung cancer detection: LuCED™. Additional diagnostic tests for gastroesophageal reflux disease (GERD), bladder cancer and other cancer types will follow.